We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Parent Age May Help Predict AD Biomarker Levels

By LabMedica International staff writers
Posted on 14 Mar 2018
Print article
Image: Postmortem tissue sample from an Alzheimer’s disease (AD) patient brain reveals AD pathology including amyloid-beta plaques and Tau tangles (Photo courtesy of Dr. Dale Bredesen).
Image: Postmortem tissue sample from an Alzheimer’s disease (AD) patient brain reveals AD pathology including amyloid-beta plaques and Tau tangles (Photo courtesy of Dr. Dale Bredesen).
Alzheimer disease (AD) develops during several decades and presymptomatic individuals might be the best candidates for clinical trials, but their identification is challenging because they have no symptoms.

Asymptomatic people with a family history of sporadic AD were more likely to show abnormal cerebrospinal fluid and brain amyloid- biomarkers as they neared their parent’s onset age, indicating that proximity to parental symptom onset may help predict amyloid- biomarker changes.

A team of scientists led by those at McGill University (Montreal, QC, Canada) analyzed amyloid-1-42 (Aβ1-42) in cerebrospinal fluid (CSF) specimens from 101 cognitively unimpaired individuals enrolled in the Presymptomatic Evaluation of Novel or Experimental Treatments for Alzheimer Disease (PREVENT-AD) cohort from September 1, 2011, through November 30, 2016. Along with a subset of the 101 PREVENT-AD participants, analysis included 128 Adult Children Study (ACS) participants (112 of whom underwent CSF measurement and 107 of whom underwent Pittsburgh compound B carbon 11–labeled positron emission tomography (PIB-PET) and 135 Wisconsin Registry for Alzheimer Prevention (WRAP) participants (85 of whom underwent CSF measurement and all of whom underwent PIB-PET).

The scientists found that PREVENT-AD participants nearing their parent’s Alzheimer’s disease onset age had lower CSF amyloid-1-42 levels; this relationship was stronger in APOE4 carriers and women. Among ACS participants, the team observed the same association using PIB-PET data, and using CSF and PIB-PET data also replicated the female sex interaction. Although the findings were not replicated using cross-sectional data among WRAP participants, the link between parent’s Alzheimer’s disease onset age and CSF amyloid- levels and the APOE interaction were replicated using PIB-PET longitudinal data.

Sylvia Villeneuve, PhD, the lead author of the study, said, “The best time window to prevent Alzheimer’s disease is likely when individuals are still asymptomatic, before extensive neuronal degeneration has occurred. Identifying asymptomatic individuals is challenging and expensive, posing significant difficulties for the current generation of clinical trials. In autosomal dominant Alzheimer’s disease, symptom onset is determinable across generations.”

The authors concluded that their results suggest that proximity to parental symptom onset may help estimate Aβ biomarker changes in women or APOE4 carrier asymptomatic individuals with a parental history of sporadic AD. The study was published on February 26, 2018, in the journal JAMA Neurology.

Related Links:
McGill University

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
HLX
Complement 3 (C3) Test
GPP-100 C3 Kit
New
Gold Member
Cancer Mutation Profiling Liquid Kit
OncoScreen Plus

Print article

Channels

Molecular Diagnostics

view channel
Image: The study showed the blood-based cancer screening test detects 83% of people with colorectal cancer with specificity of 90% (Photo courtesy of Guardant Health)

Blood Test Shows 83% Accuracy for Detecting Colorectal Cancer

Colorectal cancer is the second biggest cause of cancer deaths among adults in the U.S., with forecasts suggesting 53,010 people might die from it in 2024. While fewer older adults are dying from this... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more

Microbiology

view channel
Image: The new platform is designed to perform blood-based diagnoses of nontuberculosis mycobacteria (Photo courtesy of 123RF)

New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours

Breathing in nontuberculous mycobacteria (NTM) is a common experience for many people. These bacteria are present in water systems, soil, and dust all over the world and usually don't cause any problems.... Read more

Industry

view channel
Image: These new assays are being developed for use on the recently introduced DxI 9000 Immunoassay Analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics

Beckman Coulter Diagnostics (Brea, CA, USA) and Fujirebio Diagnostics (Tokyo, Japan) have expanded their partnership focused on the development, manufacturing and clinical adoption of neurodegenerative... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.